Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
This article was originally published in The Tan Sheet
Executive Summary
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.
You may also be interested in...
Capsugel CEO Driesen Plots Post-Pfizer Course
Guido Driesen, president and CEO of Capsugel, says the oral dosage technology firm is having a record year after being divested by Pfizer. In an interview, he discusses the firm’s applications for OTC drugs and nutritionals, as well as Capsugel’s international expansion.
Pfizer Will Unload Nutrition Division, Keep Consumer Product Unit
Pfizer will divest or spin off its nutrition unit but the firm will keep its consumer product business and look into future OTC switches.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.